Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$188 Mln
P/E Ratio
--
P/B Ratio
98.42
Industry P/E
--
Debt to Equity
-0.77
ROE
-2.61 %
ROCE
2002.9 %
Div. Yield
0 %
Book Value
--
EPS
-0.27
CFO
$-1,127.49 Mln
EBITDA
$-1,296.01 Mln
Net Profit
$-1,621.04 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
| -61.27 | -47.41 | -61.45 | -56.31 | -43.68 | -53.73 | -37.96 |
|
BSE Sensex*
| 1.83 | 3.61 | 5.06 | 9.02 | 11.22 | 21.07 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
| -26.24 | -52.01 | 24.60 | -80.77 | -56.40 | 29.63 | -30.00 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 58.65 | 11,346.08 | 26.77 | 8.05 | |
| 62.90 | 6,566.51 | 50.6 | 23.56 | |
| 56.80 | 11,265.03 | 388.07 | 0.76 | |
| 7.57 | 9,024.30 | -- | -3.24 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include... NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108 Read more
President, CEO & Director
Mr. Sheldon L. Koenig
President, CEO & Director
Mr. Sheldon L. Koenig
Headquarters
Ann Arbor, MI
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Esperion Therapeutics Inc (ESPR) stood at $ 344 Mln as on 31-Dec-24
The share price of Esperion Therapeutics Inc (ESPR) is $0.85 (NASDAQ) as of 21-Apr-2025 16:28 EDT. Esperion Therapeutics Inc (ESPR) has given a return of -43.68% in the last 3 years.
Esperion Therapeutics Inc (ESPR) has a market capitalisation of $ 188 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Esperion Therapeutics Inc (ESPR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Esperion Therapeutics Inc (ESPR) and enter the required number of quantities and click on buy to purchase the shares of Esperion Therapeutics Inc (ESPR).
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Address: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108
The CEO & director of Mr. Sheldon L. Koenig. is Esperion Therapeutics Inc (ESPR), and CFO & Sr. VP is Mr. Sheldon L. Koenig.
There is no promoter pledging in Esperion Therapeutics Inc (ESPR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,131
|
|
|
1,128
|
|
|
882
|
|
|
682
|
| Esperion Therapeutics Inc. (ESPR) | Ratios |
|---|---|
|
Return on equity(%)
|
12.27
|
|
Operating margin(%)
|
2.26
|
|
Net Margin(%)
|
-15.57
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Esperion Therapeutics Inc (ESPR) was $0 Mln.
$-0.10
(
